PDS Biotechnology (US:PDSB) — Company Overview, News & Financial Data
PDS Biotechnology develops immunotherapies for cancer and infectious diseases, utilizing its proprietary Versamune® platform.
PDS Biotechnology
PDS Biotechnology (NASDAQ:PDSB) specializes in the development of immunotherapies to fight various types of cancer and infectious diseases. Central to its operations is the Versamune® platform, a proprietary technology designed to activate the body's immune response towards specific diseases. PDS Biotechnology is currently focused on advancing its pipeline, including lead candidates for treating HPV-associated cancers and a collaboration for a COVID-19 vaccine. The company's objective is to deliver innovative treatments that improve patient outcomes and address unmet medical needs by harnessing the power of the immune system.
Snapshot
Operations
Products and/or services of PDS Biotechnology
- Versamune® technology, a platform aimed at advancing immune-activating therapies for cancer.
- PDS0101, a therapeutic vaccine targeting HPV-related cancers.
- Combination therapies leveraging PDS0101 for more effective cancer treatment options.
- Development of vaccines for infectious diseases utilizing Versamune® and other proprietary technologies.
- Research into novel immunotherapies aiming to treat a broader range of cancers.
- Collaboration with pharmaceutical companies to enhance and co-develop the existing pipeline of cancer immunotherapies.
PDS Biotechnology executive team
- Dr. Frank K. Bedu-Addo Ph.D.President, CEO & Director
- Mr. Stephan Toutain M.B.A., M.S.Chief Operating Officer
- Dr. Kirk V. Shepard M.D.Chief Medical Officer
- Mr. Lars Robert Boesgaard M.B.A.Principal Financial & Accounting Officer and CFO
- Dr. Gregory L. Conn Ph.D.Chief Scientific Officer
- Mr. Spencer Brown J.D.Senior VP, General Counsel, Corporate Secretary & Chief Compliance Officer
- Ms. Janetta TrochimiukController